
Celltrion Expands Product Portfolio in Oceania with Approvals for Idencel and Strovaklo/Ocenbelt in Australia
Celltrion announced on April 10 that it has received product approvals from the Australian Therapeutic Goods Administration (TGA) for the eye disease treatment Idencel (active ingredient: Aflibercept) and the bone disease treatment Strovaklo-Ocenbelt ( …